# A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344

> **NCT04673695** · PHASE1 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 50 (estimated)

## Conditions studied

- Anticoagulant

## Interventions

- **DRUG:** Lixiana(D006)
- **DRUG:** CKD-344

## Key facts

- **NCT ID:** NCT04673695
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-13
- **Primary completion:** 2020-12-26
- **Final completion:** 2021-01-02
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04673695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04673695, "A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04673695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*